2101 COTTONTAIL LANE, SOMERSET, NJ
Announces Preliminary Sales for CARVYKTI® for the Quarter Ended June 30, 2026
Announces Pricing of Public Offering
EHA 2026 Recap June 2026 © 2026 . All rights reserved.
First-in-human trial of LB2501, an in vivo CD19/CD20 dual targeting CAR-T therapy, in relapsed/refractory B-Cell NHL
Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
Announces Presentations at ASCO 2026
Reports First Quarter 2026 Results and Recent Highlights
Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2026
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Registration Statement for Depositary Shares, Issued upon Effectiveness
Submission Upload
Correspondence